中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

消皮素D在肝脏疾病病理进展中的作用

李飞燕 王明刚 毛德文 桂雄斌

引用本文:
Citation:

消皮素D在肝脏疾病病理进展中的作用

DOI: 10.3969/j.issn.1001-5256.2023.03.035
基金项目: 

国家自然科学基金面上项目 (82274434)

国家自然科学基金面上项目 (81774236)

国家自然科学基金 (81960841)

广西自然科学基金 (2018GXNSFGA281002)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:桂雄斌、王明刚负责对研究思路的设计,李飞燕负责查阅相关文献,资料归纳、分析,撰写论文;毛德文负责指导修改论文及最后定稿。
详细信息
    通信作者:

    桂雄斌,Guixb2008@163.com (ORCID: 0000-0002-6417-497X)

Role of gasdermin D in the pathological progression of liver diseases

Research funding: 

National Natural Science Foundation of China (82274434);

National Natural Science Foundation of China (81774236);

National Natural Science Foundation of China (81960841);

Guangxi Natural Science Foundation (2018GXNSFGA281002)

More Information
  • 摘要: 消皮素D(GSDMD)在免疫炎症反应效能放大及细胞焦亡过程中扮演重要角色。其被caspase-1切割活化后,GSDMD-N端快速释放,锚定在细胞膜上并形成孔隙,随即引发细胞焦亡,同时伴随强促炎因子IL-1β和IL-18大量释放。急/慢性肝脏炎症反应、细胞死亡是病毒性肝炎、酒精性肝病、非酒精性脂肪性肝病、自身免疫性肝病、肝衰竭及肝细胞癌等肝脏疾病的共有病理特征。本文在概述GSDMD基本结构特点后,详细分析了其在多种肝脏疾病病理进展所扮演的重要角色。此外,提出了针对GSDMD为潜在治疗靶点的防治策略,可为肝脏疾病临床防治下一步研究的重点方向提供新的思路。

     

  • [1] FRICKER M, TOLKOVSKY AM, BORUTAITE V, et al. Neuronal cell death[J]. Physiol Rev, 2018, 98(2): 813-880. DOI: 10.1152/physrev.00011.2017.
    [2] KARMAKAR M, MINNS M, GREENBERG EN, et al. N-GSDMD trafficking to neutrophil organelles facilitates IL-1β release independently of plasma membrane pores and pyroptosis[J]. Nat Commun, 2020, 11(1): 2212. DOI: 10.1038/s41467-020-16043-9.
    [3] FRANK D, VINCE JE. Pyroptosis versus necroptosis: similarities, differences, and crosstalk[J]. Cell Death Differ, 2019, 26(1): 99-114. DOI: 10.1038/s41418-018-0212-6.
    [4] YU P, ZHANG X, LIU N, et al. Pyroptosis: mechanisms and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 128. DOI: 10.1038/s41392-021-00507-5.
    [5] GAUL S, LESZCZYNSKA A, ALEGRE F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167. DOI: 10.1016/j.jhep.2020.07.041.
    [6] WANG K, SUN Q, ZHONG X, et al. Structural mechanism for GSDMD targeting by autoprocessed caspases in pyroptosis[J]. Cell, 2020, 180(5): 941-955. e20. DOI: 10.1016/j.cell.2020.02.002.
    [7] RODRÍGUEZ-ANTONIO I, LÓPEZ-SÁNCHEZ GN, URIBE M, et al. Role of the inflammasome, gasdermin D, and pyroptosis in non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2021, 36(10): 2720-2727. DOI: 10.1111/jgh.15561.
    [8] XIAO WS, LE YY, ZENG SL, et al. Role of pyroptosis in liver diseases[J]. J Clin Hepatol, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044.

    肖伟松, 乐滢玉, 曾胜澜, 等. 细胞焦亡在肝脏疾病中的作用[J]. 临床肝胆病杂志, 2020, 36(12): 2847-2850. DOI: 10.3969/j.issn.1001-5256.2020.12.044.
    [9] ZENG DY, LI JM, LIN S, et al. Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019[J]. J Hepatol, 2021, 75(3): 547-556. DOI: 10.1016/j.jhep.2021.04.035.
    [10] SETO MT, CHEUNG KW, HUNG I. Management of viral hepatitis A, C, D and E in pregnancy[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 68: 44-53. DOI: 10.1016/j.bpobgyn.2020.03.009.
    [11] CASTANEDA D, GONZALEZ AJ, ALOMARI M, et al. From hepatitis A to E: A critical review of viral hepatitis[J]. World J Gastroenterol, 2021, 27(16): 1691-1715. DOI: 10.3748/wjg.v27.i16.1691.
    [12] ZHENG M, WILLIAMS EP, MALIREDDI R, et al. Impaired NLRP3 inflammasome activation/pyroptosis leads to robust inflammatory cell death via caspase-8/RIPK3 during coronavirus infection[J]. J Biol Chem, 2020, 295(41): 14040-14052. DOI: 10.1074/jbc.RA120.015036.
    [13] AVILA MA, DUFOUR JF, GERBES AL, et al. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting[J]. Gut, 2020, 69(4): 764-780. DOI: 10.1136/gutjnl-2019-319720.
    [14] SEITZ HK, BATALLER R, CORTEZ-PINTO H, et al. Alcoholic liver disease[J]. Nat Rev Dis Primers, 2018, 4(1): 16. DOI: 10.1038/s41572-018-0014-7.
    [15] AXLEY PD, RICHARDSON CT, SINGAL AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease[J]. Clin Liver Dis, 2019, 23(1): 39-50. DOI: 10.1016/j.cld.2018.09.011.
    [16] CUI K, YAN G, XU C, et al. Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1β in mice[J]. J Hepatol, 2015, 62(6): 1311-1318. DOI: 10.1016/j.jhep.2014.12.027.
    [17] KHANOVA E, WU R, WANG W, et al. Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients[J]. Hepatology, 2018, 67(5): 1737-1753. DOI: 10.1002/hep.29645.
    [18] KUMAR S, DUAN Q, WU R, et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis[J]. Adv Drug Deliv Rev, 2021, 176: 113869. DOI: 10.1016/j.addr.2021.113869.
    [19] WANG XJ, MALHI H. Nonalcoholic fatty liver disease[J]. Ann Intern Med, 2018, 169(9): ITC65-ITC80. DOI: 10.7326/AITC201811060.
    [20] HUANG DQ, EL-SERAG HB, LOOMBA R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238. DOI: 10.1038/s41575-020-00381-6.
    [21] YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/nrgastro.2017.109.
    [22] MANNE V, HANDA P, KOWDLEY KV. Pathophysiology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis[J]. Clin Liver Dis, 2018, 22(1): 23-37. DOI: 10.1016/j.cld.2017.08.007.
    [23] WREE A, MCGEOUGH MD, PEÑA CA, et al. NLRP3 inflammasome activation is required for fibrosis development in NAFLD[J]. J Mol Med (Berl), 2014, 92(10): 1069-1082. DOI: 10.1007/s00109-014-1170-1.
    [24] XU B, JIANG M, CHU Y, et al. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice[J]. J Hepatol, 2018, 68(4): 773-782. DOI: 10.1016/j.jhep.2017.11.040.
    [25] CHEN S, CAI X, LIU Y, et al. The macrophage-associated microRNA-4715-3p/Gasdermin D axis potentially indicates fibrosis progression in nonalcoholic fatty liver disease: evidence from transcriptome and biological data[J]. Bioengineered, 2022, 13(5): 11740-11751. DOI: 10.1080/21655979.2022.2072602.
    [26] BURDETTE BE, ESPARZA AN, ZHU H, et al. Gasdermin D in pyroptosis[J]. Acta Pharm Sin B, 2021, 11(9): 2768-2782. DOI: 10.1016/j.apsb.2021.02.006.
    [27] FLOREANI A, de MARTIN S, SECCHI MF, et al. Extrahepatic autoimmunity in autoimmune liver disease[J]. Eur J Intern Med, 2019, 59: 1-7. DOI: 10.1016/j.ejim.2018.10.014.
    [28] SUCHER E, SUCHER R, GRADISTANAC T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies[J]. J Immunol Res, 2019, 2019: 9437043. DOI: 10.1155/2019/9437043.
    [29] LUAN J, ZHANG X, WANG S, et al. NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated conA-induced hepatitis[J]. Front Immunol, 2018, 9: 758. DOI: 10.3389/fimmu.2018.00758.
    [30] HUMPHRIES F, SHMUEL-GALIA L, KETELUT-CARNEIRO N, et al. Succination inactivates gasdermin D and blocks pyroptosis[J]. Science, 2020, 369(6511): 1633-1637. DOI: 10.1126/science.abb9818.
    [31] CASTILLO-DELA CRUZ P, WANEK AG, KUMAR P, et al. Intestinal IL-17R signaling constrains IL-18-Driven liver inflammation by the regulation of microbiome-derived products[J]. Cell Rep, 2019, 29(8): 2270-2283. e7. DOI: 10.1016/j.celrep.2019.10.042.
    [32] ARROYO V, MOREAU R, JALAN R. Acute-on-chronic liver failure[J]. N Engl J Med, 2020, 382(22): 2137-2145. DOI: 10.1056/NEJMra1914900.
    [33] KARVELLAS CJ, FRANCOZ C, WEISS E. Liver transplantation in acute-on-chronic liver failure[J]. Transplantation, 2021, 105(7): 1471-1481. DOI: 10.1097/TP.0000000000003550.
    [34] LI H, ZHAO XK, CHENG YJ, et al. Gasdermin D-mediated hepatocyte pyroptosis expands inflammatory responses that aggravate acute liver failure by upregulating monocyte chemotactic protein 1/CC chemokine receptor-2 to recruit macrophages[J]. World J Gastroenterol, 2019, 25(44): 6527-6540. DOI: 10.3748/wjg.v25.i44.6527.
    [35] WU YL. The role of Gasdermin D inhibitor necrosulfonamide in acute liver failure[D]. Fuzhou: Fujian Medical University, 2020. DOI: 10.27020/d.cnki.gfjyu.2020.001021" target="_blank">10.27020/d.cnki.gfjyu.2020.001021.

    吴奕隆. Gasdermin D抑制剂necrosulfonamide在急性肝衰竭中作用[D]. 福州: 福建医科大学, 2020. DOI: 10.27020/d.cnki.gfjyu.2020.001021" target="_blank">10.27020/d.cnki.gfjyu.2020.001021.
    [36] YU LX, SCHWABE RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539. DOI: 10.1038/nrgastro.2017.72.
    [37] GALICIA-MORENO M, SILVA-GOMEZ JA, LUCANO-LANDEROS S, et al. Liver Cancer: therapeutic challenges and the importance of experimental models[J]. Can J Gastroenterol Hepatol, 2021, 2021: 8837811. DOI: 10.1155/2021/8837811.
    [38] FU J, WANG H. Precision diagnosis and treatment of liver cancer in China[J]. Cancer Lett, 2018, 412: 283-288. DOI: 10.1016/j.canlet.2017.10.008.
    [39] CHEN YF, QI HY, WU FL. Euxanthone exhibits anti-proliferative and anti-invasive activities in hepatocellular carcinoma by inducing pyroptosis: preliminary results[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8186-8196. DOI: 10.26355/eurrev_201812_16511.
    [40] LIU X, XIA S, ZHANG Z, et al. Channelling inflammation: gasdermins in physiology and disease[J]. Nat Rev Drug Discov, 2021, 20(5): 384-405. DOI: 10.1038/s41573-021-00154-z.
  • 加载中
计量
  • 文章访问数:  320
  • HTML全文浏览量:  65
  • PDF下载量:  19
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-08-20
  • 录用日期:  2022-10-16
  • 出版日期:  2023-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回